• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Author Archive for: "Nascent Biotech"
 Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial
0
By Nascent Biotech
In Uncategorized
Posted January 25, 2023

Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial

NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 NBIO Fits Profile for Strategy Targeting Early Stage Biotech
0
By Nascent Biotech
In Corporate News
Posted January 18, 2023

NBIO Fits Profile for Strategy Targeting Early Stage Biotech

One candidate that checks all of these boxes is Nascent Biotech Inc. (OTCMKTS:NBIO). NBIO checks all the boxes discussed above. It’s a dirt-cheap stock, trading on a market cap of just $16 [...]

READ MORE
 Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial
0
By Nascent Biotech
In News, Press Releases, Science News
Posted January 10, 2023

Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial

NORTH PALM BEACH, FL / ACCESSWIRE / January 10, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted December 20, 2022

Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board

VERO BEACH, FL / ACCESSWIRE / December 20, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394
0
By Nascent Biotech
In Corporate News, News, Press Releases, Science News
Posted November 1, 2022

Nascent Biotech Receives Notice of the Issuance of US Patent No.11,494,394

VERO BEACH, FL / ACCESSWIRE / November 1, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted October 4, 2022

Nascent Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research

VERO BEACH, FL / ACCESSWIRE / October 4, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
0
By Nascent Biotech
In Corporate News, Press Releases, Science News
Posted September 13, 2022

Nascent Biotech Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

VERO BEACH, FL / ACCESSWIRE / September 13, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent
0
By Nascent Biotech
In Science News
Posted July 19, 2022

Nascent Biotech Receives Notice of Allowance from USPTO for Issuance of Additional Patent

VERO BEACH, FL / ACCESSWIRE / July 19, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Biotech Inc (OTCMKTS: NBIO) Steady Rise Northbound as Phase 1 Clinical Trials Progress for Pritumumab (PTB) Targeting Glioblastoma
0
By Nascent Biotech
In Corporate News
Posted June 14, 2022

Nascent Biotech Inc (OTCMKTS: NBIO) Steady Rise Northbound as Phase 1 Clinical Trials Progress for Pritumumab (PTB) Targeting Glioblastoma

Nascent Biotech Inc (OTCMKTS: NBIO) is making a steady run northbound off its base at a nickel and saw some of its biggest gains while the overall markets saw steep declines. NBIO is a low float [...]

READ MORE
 Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
0
By Nascent Biotech
In Science News
Posted June 7, 2022

Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

VERO BEACH, FL / ACCESSWIRE / June 7, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
1 2 3 4 5 6 7 8 9
page 1 of 9
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.